Charles S. Berkman

2020 - Ligand Pharmaceuticals

In 2020, Charles S. Berkman earned a total compensation of $1.9M as Senior Vice President and General Counsel at Ligand Pharmaceuticals, a 4% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$176,767
Option Awards$675,820
Salary$441,917
Stock Awards$644,168
Other$6,180
Total$1,944,852

Berkman received $675.8K in option awards, accounting for 35% of the total pay in 2020.

Berkman also received $176.8K in non-equity incentive plan, $441.9K in salary, $644.2K in stock awards and $6.2K in other compensation.

Rankings

In 2020, Charles S. Berkman's compensation ranked 5,646th out of 13,090 executives tracked by ExecPay. In other words, Berkman earned more than 56.9% of executives.

ClassificationRankingPercentile
All
5,646
out of 13,090
57th
Division
Manufacturing
2,331
out of 5,621
59th
Major group
Chemicals And Allied Products
930
out of 2,254
59th
Industry group
Drugs
804
out of 1,954
59th
Industry
Pharmaceutical Preparations
598
out of 1,459
59th
Source: SEC filing on April 22, 2022.

Berkman's colleagues

We found three more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2020.

2020

John Higgins

Ligand Pharmaceuticals

Chief Executive Officer

2020

Matthew Foehr

Ligand Pharmaceuticals

Chief Operating Officer

2020

Matthew Korenberg

Ligand Pharmaceuticals

Chief Financial Officer

News

You may also like